U.S Futures rising – Watch REGN, TSLA, NFLX

,

The S&P 500 Futures are rebounding after they closed in the red on Friday

Trading floor 2

The S&P 500 Futures are rebounding after they closed in the red on Friday.

Later today, the Federal Reserve Bank of Chicago will post October National Activity Index (0.27 expected). Research firm Markit will publish preliminary readings of November Manufacturing PMI (52.5 expected) and November Services PMI (55.8 expected).

European indices are on the upside. AstraZeneca announced that its candidate vaccine developed with Oxford University is 70% effective on average. Research firm Markit has published preliminary readings of November Manufacturing PMI for the eurozone at 53.6 (vs 54.2 expected), for Germany at 57.9 (vs 57.3 expected), for France at 49.1 (vs 49.9 expected) and for the U.K. at 55.2 (vs 51.6 expected). Also, the preliminary readings of November Services PMI for the eurozone was published at 41.3 (vs 44.1 expected), at 46.2 for Germany (vs 47.5 expected), at 38.0 for France (vs 39.0 expected) and at 45.8 for the U.K. (vs 46.0 expected).

Asian indices closed slightly on the upside except the Hong Kong HSI. The Japanese Nikkei was closed for holiday.

WTI Crude Oil remains strong. The total number of rotary rigs in the U.S. slipped to 310 as of November 20 from 312 in the prior week, while rigs in Canada rose to 101 from 89, according to Baker Hughes.

U.S indices closed down on Friday, pressured by Banks (-1.15%), Consumer Services (-1.14%) and Software & Services (-1.13%) sectors.

Approximately 90% of stocks in the S&P 500 Index were trading above their 200-day moving average and 81% were trading above their 20-day moving average. The VIX Index rose 0.59pt (+2.55%) to 23.7 and WTI Crude Oil jumped $0.5 (+1.19%) to $42.4 at the close.

Gold and U.S dollar consolidate as investors favor riskier assets currently.

Gold fell 3.86 dollars (-0.21%) to 1867.13 dollars.

The dollar index declined 0.34pt to 92.056.


U.S. Equity Snapshot


Regeneron Pharmaceuticals (REGN), a biotechnology company, reported that its REGEN-COV2, an antibody cocktail for Covid-19, has received Emergency Use Authorization from the U.S. Food and Drug Administration. The company said it "now expects to have REGEN-COV2 treatment doses ready for approximately 80,000 patients by the end of November, approximately 200,000 patients by the first week of January, and approximately 300,000 patients in total by the end of January 2021".


Source: TradingView, GAIN Capital

Tesla (TSLA)'s, the electric-vehicle maker, price target was raised to 560 dollars from 500 dollars at Wedbush.

Netflix (NFLX)'s, the video streaming service, target price was raised to 628 dollars from 615 dollars at JPMorgan.

More from Equities

From time to time, GAIN Capital Australia Pty Ltd (“we”, “our”) website may contain links to other sites and/or resources provided by third parties. These links and/or resources are provided for your information only and we have no control over the contents of those materials, and in no way endorse their content. Any analysis, opinion, commentary or research-based material on our website is for information and educational purposes only and is not, in any circumstances, intended to be an offer, recommendation or solicitation to buy or sell. You should always seek independent advice as to your suitability to speculate in any related markets and your ability to assume the associated risks, if you are at all unsure. No representation or warranty is made, express or implied, that the materials on our website are complete or accurate. We are not under any obligation to update any such material.

As such, we (and/or our associated companies) will not be responsible or liable for any loss or damage incurred by you or any third party arising out of, or in connection with, any use of the information on our website (other than with regards to any duty or liability that we are unable to limit or exclude by law or under the applicable regulatory system) and any such liability is hereby expressly disclaimed.